Top

Published in:

01-10-2012

The frequency of factor V Leiden and prothrombin G20210A mutations in Slovak and Roma (Gypsy) ethnic group of Eastern Slovakia

Authors: Alexandra Bôžiková, Dana Gabriková, Adriana Sovičová, Regina Behulová, Soňa Mačeková, Iveta Boroňová, Eva Petrejčíková, Miroslav Soták, Jarmila Bernasovská, Ivan Bernasovský

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2012

Abstract

Factor V Leiden and prothrombin G20210A are the two most prevalent causes of inherited thrombophilia. The prevalence of these mutations varies widely in healthy Caucasian population. The aim of our study was to determine the frequency of factor V Leiden and prothrombin G20210A mutations in Slovak and Roma ethnic group from Eastern Slovakia. We analyzed 540 asymptomatic individuals (269 individuals of Slovak ethnicity and 271 individuals of Roma ethnicity) by real-time PCR method. The detected allele frequencies were 2.97 versus 6.64 % for factor V Leiden (p = 0.0049), and 0.74 versus 0.92 % for prothrombin mutation (p = 0.7463) in Slovak and Roma population, respectively. The Roma ethnic group had significantly higher prevalence of factor V Leiden mutation when compared to Slovak ethnic group. The allele frequency of factor V Leiden in ethnic Romanies from Eastern Slovakia was one of the highest in Europe. Our results confirm an uneven geographical and ethnic distribution of factor V Leiden.

Rosendaal FR (1997) Thrombosis in the young: epidemiology and risk factors: a focus on venous thrombosis. Thromb Haemost 78(1):1–6PubMed

Bertina RM, Koeleman BPC, Koster T et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369(6475):64–67. doi:10.1038/369064a0 PubMedCrossRef

Zivelin A, Griffin JH, Xu X et al (1997) A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 89:397–402PubMed

Rees DC, Cox M, Clegg JB (1995) World distribution of factor V Leiden. Lancet 346:1133–1134PubMedCrossRef

Irani-Hakime N, Tamim H, Kreidy R et al (2000) The prevalence of factor V R506Q mutation-Leiden among apparently healthy lebanese. Am J Hematol 65(1):45–49. doi:10.1002/1096-8652(200009)65:1<45:AID-AJH8>3.0.CO;2-V PubMedCrossRef

Herrmann FH, Koesling M, Schröder W et al (1997) Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol 14:403–411. doi:10.1002/(SICI)1098-2272(1997)14:4<403:AID-GEPI5>3.0.CO;2-3 PubMedCrossRef

Rosendaal FR (1999) Risk factors for venous thrombotic disease. Thromb Haemost 82:610–619PubMed

Rosendaal FR, Koster T, Vanderbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504–1508PubMed

Plameňová I, Bartošová L, Chudej J et al (2011) National registry of thrombophilic states in Slovak republic (article in slovak). Vask Med 3(2):I–V, electronic supplement

10.

Poort SR, Rosendaal FR, Reitsma PH et al (1996) A common genetic variation in the 3′untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed

11.

Rosendaal FR, Doggen C, Zivelin A et al (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706–708PubMed

12.

Zivelin A, Rosenberg N, Faier S et al (1998) A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 92:1119–1124PubMed

13.

Liegeois J-P (1994) Roma, Gypsies, Travellers. Council of Europe Press, Strasbourg

14.

Marushiakova E, Popov V (2001) Historical and ethnographic background. Gypsies, Roma, Sinti. In: Guy W(ed) Between past and future: the Roma of Central and Eastern Europe. University of Hertfordshire Press, Hatfield, pp 33–53

15.

Ferák V, Siváková D, Sieglová Z (1987) The slovak gypsies (Romany): population with the highest coeficient of inbreeding in Europe (article in slovak). Bratisl Lek Listy 87:168–175PubMed

16.

Bernasovský I, Bernasovská J (1999) Antropology of Romanies. Auxological and Anthropogenetical study. Nauma, Brno

17.

Petrejčíková E, Soták M, Bernasovská J et al (2009) Y-haplogroup frequencies in the Slovak Romany population. Anthropol Sci 117:89–94. doi:10.1537/ase.080422 CrossRef

18.

Ginter E, Havelková B, Kudláčková M et al (2004) Differences in health status of different regions of Slovakia. Roma population (article in slovak). Med Monitor 6:14–16

19.

Paseka J, Unzeitig V, Cibula D et al (2000) The factor V Leiden mutation in users of hormonal contraceptives. Ceska Gynekol 65:156–159PubMed

20.

Sucker C, Kurschat C, Hetzel GR et al (2009) The G1691A mutation of the factor V gene (Factor V Leiden) and the G20210A mutation of the prothrombin gene as risk factors in thrombotic microangiopathies. Clin Appl Thromb Hemost 15:360–363. doi:10.1177/1076029607311778 PubMedCrossRef

21.

Lalouschek W, Schillinger M, Hsieh K et al (2005) Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke 36(7):1405–1409. doi:10.1161/01.STR.0000170635.45745.b8 PubMedCrossRef

22.

Lopaciuk S, Bykowska K, Kwiecinski H et al (2001) Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost 7(4):346–350PubMedCrossRef

23.

Kubisz P, Staško J, Pullmann R (2002) Epidemiology of inherited thrombophilia in Slovak population. Int J Hematol Suppl 76(1):122

24.

Procházka M, Lubušký M, Slavík L et al (2007) Frequency of selected thrombophilias in women with placental abruption. Aust N Z J Obstet Gynaecol 47(4):297–301. doi:10.1111/j.1479-828X.2007.00741.x PubMedCrossRef

25.

Chudej J, Plameňová I, Hollý P et al (2011) Prevalence of prothrombin mutation gene (G-A 20210) in thrombophilic patients and in healthy population (article in slovak). Lek Obz 60(4):155–161

26.

Balogh I, Póka R, Losonczy G et al (1999) High frequency of factor V Leiden mutation and prothrombin 20210A variant in Romanies of Eastern Hungary. Thromb Haemost 82(5):1555–1556PubMed

27.

Nagy M, Henke L, Henke J et al (2007) Searching for the origin of Romanies: slovakian Romani, Jats of Haryana and Jat Sikhs Y-STR data in comparison with different Romani populations. Forensic Sci Int 169(1):19–26. doi:10.1016/j.forsciint.2006.07.020 PubMedCrossRef

28.

Garewal G, Das R, Trehan U (1997) Factor V prevalence in the indigenous population and cases of thrombosis in North India. Br J Haematol 97(4):940PubMed

29.

Pawar AR, Ghosh K, Shetty S et al (2000) High frequency of factor V Leiden mutation in Parsis––a highly endogamous population in India. Thromb Haemost 83(6):965PubMed

30.

Gupta N, Khan F, Tripathi M et al (2003) Absence of factor V Leiden (G1691A) mutation, FII G20210A allele in coronary artery disease in North India. Indian J Med Sci 57(12):535–542PubMed

31.

Ghosh K, Khare A, Kulkarni B et al (2004) Geography too determines the causes of inherited thrombophilia. J Thromb Haemost 2(2):363–364PubMedCrossRef

32.

Rees DC, Chapman NH, Webster MT et al (1999) Born to clot: the European burden. Br J Haematol 105(2):564–566. doi:10.1111/j.1365-2141.1999.01361.x PubMedCrossRef

33.

Gresham D, Morar B, Underhill PA et al (2001) Origins and divergence of the Roma (Gypsies). Am J Hum Genet 69(6):1314–1331PubMedCrossRef

34.

Mendizabal I, Valente C, Gusmão A et al (2011) Reconstructing the Indian origin and dispersal of the European Roma: a maternal genetic perspective. PLoS ONE 6(1):e15988. doi:10.1371/journal.pone.0015988 PubMedCrossRef

Title: The frequency of factor V Leiden and prothrombin G20210A mutations in Slovak and Roma (Gypsy) ethnic group of Eastern Slovakia
Authors: Alexandra Bôžiková
Dana Gabriková
Adriana Sovičová
Regina Behulová
Soňa Mačeková
Iveta Boroňová
Eva Petrejčíková
Miroslav Soták
Jarmila Bernasovská
Ivan Bernasovský
Publication date: 01-10-2012
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2012
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-012-0736-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

The in vitro effects of verbascoside on human platelet aggregation

A case of IVC filter thrombosis

Impact of smoking status on outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

The relationship between intracranial arterial stenosis and glomerular filtration rate

Diagnosis and endovascular treatment of acute thromboembolic renal artery occlusion presenting with abdominal pain

The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials